Pharmaceutical/Medical Devices

As scientific and technological development in the medical, pharmaceutical and healthcare fields continues its explosive growth, Oblon Spivak is at the forefront of helping companies identify, protect, license and enforce intellectual property in these important areas. In the pharmaceutical industry alone, billions of dollars are invested in research and development with few drugs actually surviving clinical trials, regulatory clearances and product launch. With such a great investment, companies need skilled attorneys to protect their innovations.

Our clients include both domestic and foreign companies, including major Asian and European companies developing medicines, medical devices, procedures and treatments. We pride ourselves on our longstanding relationships with our clients, many of whom we have represented for more than 40 years. We have the resources and experience to formulate and execute global patent protection strategies for our clients, regularly appearing on their behalf in the United States Patent and Trademark Office (USPTO), before the International Trade Commission (ITC), and courts throughout the United States.

FDA Expertise

In addition to biotechnology and pharmaceutical patent protection, we have specific expertise analyzing the impact of the U.S. Food and Drug Administration’s (FDA) regulations and working within the regulatory framework to identify opportunities, address challenges and provide the broadest patent protection possible for our clients’ intellectual property. We regularly advise clients on lifecycle management (LCM) and patent portfolio enhancement, often handling patent term extensions, exclusivity protection, design-arounds, abbreviated new drug (ANDA) litigation, and other infringement challenges.

Skilled Team of Professionals

Oblon Spivak’s success begins with a distinguished professional staff that includes attorneys with a high level of scientific and technical training in the areas of chemistry, biology, biotechnology, biomedical engineering, medicine, and the electrical and mechanical arts, all of which can play a significant role in pharmaceutical and medical innovations. Many of our lawyers are Ph.D.s whose graduate research directly involved biotechnology. Team members include litigators, attorneys with industry experience and former Patent Examiners with the USPTO.

Strategic Location

In addition to our sophisticated technical backgrounds, our Alexandria, Virginia location-adjacent to the USPTO-enables us to regularly meet face-to-face with USPTO Patent Examiners, enhancing our ability to obtain protection for our clients' inventions while keeping cost to a minimum. Our close working relationship with the USPTO is an important factor contributing to our record of success in obtaining patent protection for our clients.

Comprehensive Intellectual Property Protection

Fully safeguarding inventions sometimes calls for measures beyond patents. We have confronted virtually every type of intellectual property issue in the pharmaceutical and medical device fields and handle all aspects of safeguarding our clients’ innovations, including:

  • Developing and implementing patent prosecution strategies
  • Preparing and negotiating licensing and co-development agreements
  • Providing due diligence and risk assessments for mergers and acquisitions and other business transactions
  • Counseling on antitrust, exclusivity and competition issues
  • Advising on potential litigation strategies, and asserting and defending patents in court
  • Advising on product lifecycle management
  • Representing clients in complex Hatch-Waxman litigation
  • Working collaboratively with our Litigation, Post Grant and Patent Interferences practice groups to fully protect our clients’ innovations
  • Obtaining FDA exclusivities for client products
  • Addressing generic competition

We are experienced with branded products, as well as representation of generic product developers and manufacturers, product launches, the protection of biosimilars, and strategic use of citizens’ petitions to forestall competition.

Forward-Thinking Counsel

As biotechnology development continues to outpace the law, courts are constantly reviewing and revising earlier opinions on patentability, infringement, and issues of public policy. We help clients protect themselves against these legal uncertainties through strategies that build on other legal safeguards, such as trade secret protection and contract protection. By helping our clients incorporate these and other non-patent protection schemes into their portfolios, we assist them in ensuring that they achieve superior commercial success.

Tuesday, March 01, 2011

The Senate and House of Representatives are both considering bills that would prevent NDA holders from marketing authorized generic versions of their drug during a generic manufacturer’s 180-day exclusivity.

Thursday, February 03, 2011

The FDA announced, in a January 19, 2011 press release, its plans to improve procedures regarding medical devices under...

Thursday, February 03, 2011

Senator Herb Kohl (D-WI) recently introduced the Preserve Access to Affordable Generics Act (S.27) concerning patent settlements with payments from an NDA holder to an ANDA filer. If enacted, the act would allow the FTC to presume anticompetitive...

Thursday, January 20, 2011

Genetics & IVF Institute, an exclusive licensee of a patent owned by the U.S. Department of Agriculture (USDA), recently served a complaint on the USPTO for suit in the U.S. District Court for the Eastern District of Virginia.  The suit related to a petition that Genetics & IVF filed with the USPTO for an extension of time to file...

Thursday, January 20, 2011

Apotex filed suit against Forest Labs on Monday, January 10, seeking declaratory judgment of non-infringement based on Apotex’s ANDA and accompanying Paragraph IV certification for escitalopram oxalate (Lexapro®), an antidepressant.

Thursday, January 13, 2011

In a case involving reverse payment settlements, the attorneys general of 32 states filed an amicus brief on Friday, January 7 arguing that the Supreme Court should grant a writ of certiorari in Louisiana Wholesale Drug Co. v.

Wednesday, January 12, 2011

Caraco Pharmaceutical and Sun Pharmaceutical recently petitioned the Supreme Court for a writ of certiorari in their case against Novo Nordisk regarding availability of an Orange Book correction counterclaim to an infringement action.  The Federal Circuit ...

Wednesday, December 01, 2010

Affirming an appeal from the D.C. District Court, the Court of Appeals for the D.C. Circuit ruled on November 9 in favor of the FDA’s position on drug molecules containing previously-approved active ingredients covalently bonded to further chemical components.  The FDA position, before and after this ruling, is that a molecule held...

Friday, November 12, 2010

In a 5-4 split, the Federal Circuit denied a petition for a panel rehearing and a rehearing en banc in Sun Pharm. v. Eli Lilly on November 1.

Friday, November 12, 2010

The FDA recently granted NDA holder Genzyme’s petition for a superseding 30-month stay against approval of Cobrek’s generic version of Genzyme’s Hectorol drug.